The Establishment of an HE4‐CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer

Zhang, Qiong; Wang, Congrong; Yu, Jie-Ping; Ma, Qiang; Xu, Weiwen

doi:10.1002/jcla.21926

Cited by 8 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diagnostic values of CA125 and CA199 alone and in combination, and ultrasound and CT alone and in combination in ovarian cancer were further analyzed. Studies have proved that the accuracy of serum CA125 and CA199 alone in diagnosis of ovarian cancer is lower than that of CA125 combined with CA199 (17,18), and accuracy of ultrasound and CT alone was lower than that of ultrasound combined with CT (19). This is in line with our experimental conclusion that the accuracy of CA125 and CA199 alone in diagnosis was low.…”

Section: Discussionmentioning

confidence: 99%

Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer

Guo¹,

Lian

Liu

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Application values of CA125 combined with CA199 and ultrasound combined with computed tomography (CT) in the clinical diagnosis of ovarian cancer were compared. A retrospective analysis was performed on 168 ovarian cancer patients admitted to the Department of Gynecology in Jining No.1 People's Hospital from July 2013 to March 2016. Of the patients 107 with malignant tumors were in the malignant group, and 61 patients with benign tumors were in the benign group. Another 98 healthy controls in the same period were in the normal group. Chemiluminescence was used for the detection of levels of tumor markers CA125 and CA199 in the serum of all patients. CA125 combined with CA199 and color Doppler ultrasound combined with CT scan were used to diagnose and analyze the sensitivity, specificity, accuracy, and positive detection rate of ovarian cancer patients at different stages. The sensitivity, specificity and diagnostic coincidence rate of ultrasound combined with CT in the diagnosis of ovarian cancer were 97.20, 80.32 and 91.07%, respectively, which were significantly higher than the 92.52, 73.77 and 85.71% of serum CA125 combined with CA199. The positive detection rate of ultrasound combined with CT in the early diagnosis of ovarian cancer was 93.55%, higher than 83.87% of CA125 combined with CA199. The sensitivity, specificity, coincidence rate and positive detection rate of ultrasound combined with CT in the diagnosis were higher than those of CA125 combined with CA199. In the actual diagnosis process, these two diagnostic schemes can be selectively and comprehensively applied, so as to make a correct diagnosis, which is of great significance for reducing patient mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer

Guo¹,

Lian

Liu

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Assays measuring tumor markers in serum or other body fluids have the advantage of being noninvasive, simple to perform and relatively cheap. Since one among 2500 postmenopausal women is likely to develop ovarian carcinoma in the USA, an acceptable screening assay would require a sensitivity of 75% and specificity of about 99.7% to obtain minimally tolerable positive predictive value of 10% for the detection of ovarian carcinoma [24][25][26] . The main tools we used were clinical manifestations, estimation of serum CA125 and calculation of the RMI for the study population, and applying different ultrasound features on the adnexal masses in these cases, but a single method which can accurately predict ovarian malignancy is still unavailable.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Calculated Risk of Malignancy Index as a Predictor of the Nature of Adnexal Masses

Mostafa

Assem

Ibrahim

2022

International Journal of Medical Arts

View full text Add to dashboard Cite

Article informationBackground: Adnexal masses are common presentation among gynecological practice. Differentiation of benign than malignant lesions is of utmost importance for treatment plan. The gold standard other than histopathology did not determined yet. The aim of the work: The current work aimed to measure the predictive power of the preoperative risk of malignancy index [RMI] to discriminate between benign and malignant adnexal masses. Patients and Methods: This study included 80 patients, presented with adnexal masses/ovarian cysts. They were managed by surgery, during the period from May 2015 to November 2017. We collected the following data: age, gravidity, menopause status, parity, cancer antigen 125 [CA125] levels and ultrasound results. RMI was calculated according to Tingulstad" model. Postoperatively, histopathology results were documented for every patient and used as the gold standard diagnostic modality to measure predictive power of RMI and CA125. Results: Malignant lesions were documented in 27.5%, while 72.5% were benign. The benign tumors were significantly associated with younger age than malignant lesions [27.88±7.68 versus 41.05±11.81]. The postmenopausal women percentages were significantly higher among malignant than benign ovarian lesions [45.5% vs. 1.7%, respectively, p < 0.001]. All ultrasound parameters of RMI were significantly different in malignant than benign masses. The optimal cutoff points of RMI and CA125 were 90.6 and 20.0 respectively. At such points, RMI had 90.6 sensitivity. However, specificity, positive predictive value, negative predictive values were 68.2%, 75.9%, 51.7% and 86.3%, respectively. Conclusion: RMI represented a significant indicator in preoperative assessment of adnexal mass, and was valuable to refer patients to oncology centers, and recommended for screening purposes.

show abstract

“…Currently, chemiluminescence immunoassay (CLIA) is recognized as the most sensitive classical method in immunologic diagnosis [15] , [16] , with the significant merits of high sensitivity, low noise, broader linearity, reduced assay time, free of radioactive reagents, and easy to use. Meanwhile, the light intensity of chemiluminescence (CL) reaches its maximum within 1–2 min after substrate addition, thus shortening the overall analytical procedure when compared with the conventional colorimetric assays.…”

Section: Introductionmentioning

confidence: 99%

The fabrication of magnetic particle-based chemiluminescence immunoassay for human epididymis protein-4 detection in ovarian cancer

Liu

Qiu

et al. 2018

Biochemistry and Biophysics Reports

View full text Add to dashboard Cite

The magnetic particles have a significant influence on the immunoassay detection and cancer therapy. Herein, the chemiluminescence immunoassay combined with the magnetic particles (MPCLIA) was presented for the clinical determination and analysis of human epididymis protein 4 (HE4) in the human serum. Under the optimized experiment conditions, the secure MPCLIA method can detect HE4 in the broader range of 0–1000 pmol/L, with a lower detection limit of 1.35 pmol/L. The satisfactory recovery rate of the method in the serum ranged from 83.62% to 105.10%, which was well within the requirement of clinical analysis. Moreover, the results showed the good correlation with enzyme-linked immunosorbent assay (ELISA), with the correlation coefficient of 0.9589. This proposed method has been successfully applied to the clinical determination of HE4 in the human serum.

show abstract

The Establishment of an HE4‐CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer

Cited by 8 publications

References 31 publications

Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer

Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer

Evaluation of the Calculated Risk of Malignancy Index as a Predictor of the Nature of Adnexal Masses

The fabrication of magnetic particle-based chemiluminescence immunoassay for human epididymis protein-4 detection in ovarian cancer

Contact Info

Product

Resources

About